#CancerDrug

[thxnews]

Innovent Revolutionizes Cancer Care at AACR

At the 2024 AACR Meeting, Innovent Biologics will unveil groundbreaking preclinical data on novel bispecific antibodies and ADCs, heralding a significant advancement in oncology and promising new, effective cancer treatments. This represents a pivotal moment in the fight against cancer.  

IBI3001: The Vanguard of Innovent's Arsenal

At the heart of Innovent's presentation is IBI3001, a novel anti-cancer drug that embodies the cutting-edge of therapeutic design. This site-specific glycan-conjugated B7-H3/EGFR bispecific ADC aims at tackling multiple solid tumors with unprecedented precision.   Dr. Kaijie He, Innovent's Vice President,  stated: “We are pleased that the pre-clinical studies of our novel anti-cancer drugs are accepted for Late-Breaking Research poster presentation at the 2024 AACR conference. This is the result of dedicated work from scientists at Innovent Academy with the aim to tackle cancers with innovative drugs that are more effective and safer. With careful design and optimization, our molecules can achieve favorable therapeutic windows of 40 to more than 200 times. We look forward to their performance in clinical settings and hope that these innovations can eventually benefit cancer patients.”  

A Spectrum of Innovation

In addition to IBI3001, Innovent is gearing up to reveal preclinical findings on a TROP2-targeted immune stimulating antibody conjugate (ISAC). This novel molecule demonstrates potent anti-tumoral activity coupled with an acceptable safety profile, promising a brighter future for cancer patients. Dr. He is optimistic about the therapeutic windows these innovations could open, with favorable ratios ranging from 40 to over 200 times, underscoring their potential efficacy in clinical settings.   The Bigger Picture: Confronting Cancer Cancer's toll on global health remains staggering, with millions of lives claimed annually. It's a battle fought on multiple fronts: genetic predispositions, lifestyle factors, and the dire need for effective treatments. Herein lies the importance of Innovent's work, aiming not only to extend the frontier of cancer treatment but also to offer hope to those embroiled in this fight. The company's contributions to early detection and treatment could significantly alter the landscape of cancer care, emphasizing the importance of continuous innovation in the medical field.  

Toward a Future Without Cancer

Innovent Biologics' presentation at the 2024 AACR Annual Meeting stands as a testament to the relentless pursuit of medical advancement. As we edge closer to unraveling the complexities of cancer, the contributions of companies like Innovent illuminate the path forward, promising a future where cancer's grip on humanity is significantly weakened.   Sources: THX News & Innovent Biologics, Inc.. Read the full article

[richardsphere]

Leverage Log: The Boys Night Out Job

Wait... Is that Hurley from Season 1? The rehab job? That guy?

I guess yeah, he was a good person at heart (just also an idiot) and he never went to prison or anything... Its just a weird bit of continuity to see (i was expecting maybe those 2 FBI guys or something). Wait HURLEY is the guy that almost hit Himbo with a car in the Girls Night cold open?

back to the shared scene from last episode... "And dont say maggie"... OH thats why Sophie didnt like "Marge" as an alias last episode. Cause its short for Margaret...

Hurley arives to find Nate, who he knows has a drinking problem holding a glass and is instantly worried for him.

"when you helped me" "we were trying to take you down for embezzlement"

Oh no... Nate instantly recognises "this idiot is making cross-the-border deliveries for a mexican cartel isnt he..."

Hurley's defense that he's no longer a criminal and that clearly they must be after Nate. The guy who is still an out and open criminal. The picture of an actual swimsuitmodel on his phone that he legitimately believes is a nun.

Nate is stuck at an Alcoholics Anonymous meeting with Hurley. He's been in prisons and actual torturechairs more comfortable then an this.

---

The goons are arguing the semantics of Basements and Holy Ground...

--- Im gonna be honest, im kind of dissapointed we havent actually gotten to see our guys interact with Bonanno yet. But yeah they are not coming back with the pizza any time soon.

Wait... Hurleys been smuggling cancer drugs? Or is Lupe actually lying... Cause that is verry much something i could see...

---

"im a dirty cop, of course im a racist". --- "rapture!"

--- Ok, so Hurley is just not allowed to own wheeled vehicles anymore right? Like every car of his just becomes a vessel for criminal enterprise. --- So... She's actually smuggling the cancerdrugs. Probably not an actual nun... Hurleys willing to go for the sacrifice play

Peggy and Hurley going out together... thats cute. Hardisons reason for telling Hurley where to find Nate is sweet.

---

So... did we ever find out what the people searching the hotelroom were looking for? Cause they werent looking for drugs (the venezuelan goons were very much not involved in the drug plot. it just happened to happen in the same hotel) and the information hadn't even been stolen yet. (unless they thought it had already been stolen? I guess it was "copied" rather then "stolen" so...)

So i guess they must've thought it had been stolen already and were trying to double-cross the guy they hired to steal it for them? That makes no sense? I assume im missing something.

kind of sad we dont get to see Nate and Bonanno actually share a proper scene. I thought this would be our one shot but it just keeps not happening.

[neosciencehub]

Price of Hope: Unpacking the Govt’s Tax Cut on Lifesaving Cancer Drugs @neosciencehub #CancerDrugs #Lifesaving #Taxcut #Sciencenews #Healthcare

[globalinsightblog]

Non-Hodgkin Lymphoma Therapeutics Market Projected to Reach $18.5B by 2034 💉

Non-Hodgkin Lymphoma (NHL) Therapeutics Market is set to expand from $10.2 billion in 2024 to $18.5 billion by 2034, with a CAGR of 5.8%. This growth is fueled by advancements in targeted therapy, immunotherapy, and personalized medicine, improving survival rates and patient outcomes. The demand for novel biologics and combination therapies continues to reshape the oncology landscape.

To Request Sample Report: https://www.globalinsightservices.com/request-sample/?id=GIS10678 &utm_source=SnehaPatil&utm_medium=Article

Key Market Trends & Drivers

✅ Immunotherapy Breakthroughs — CAR T-cell therapy leads the market, offering a revolutionary approach for relapsed or refractory NHL patients. ✅ Targeted Therapy Expansion — Monoclonal antibodies and small molecule inhibitors enhance treatment precision, reducing side effects compared to traditional chemotherapy. ✅ Combination Therapies on the Rise — The use of immunotherapy with chemotherapy (chemo-immunotherapy) improves efficacy, particularly in aggressive NHL subtypes. ✅ Personalized Medicine Growth — Advances in biomarker-driven treatment and gene editing pave the way for customized cancer treatment strategies. ✅ Rising NHL Incidence Rates — The growing elderly population and increasing risk factors such as immune disorders and infections drive market demand.

Regional Market Outlook

📍 North America leads, driven by high healthcare expenditure, strong R&D funding, and early adoption of advanced therapies. 📍 Europe follows, with Germany and the UK leading due to government-backed clinical research and improved patient access to therapies. 📍 Asia-Pacific emerges as a high-growth region, fueled by expanding healthcare infrastructure in China and India, rising NHL prevalence, and increased awareness of advanced treatments.

With ongoing research in gene therapy, bispecific antibodies, and AI-driven drug discovery, the NHL therapeutics market is set for a decade of transformative advancements.

#NonHodgkinLymphoma #CancerTreatment #CAR-T #OncologyResearch #Immunotherapy #TargetedTherapy #PrecisionMedicine #CancerInnovation #LymphomaAwareness #PersonalizedMedicine #CancerSurvivor #Biologics #GeneTherapy #PharmaInnovation #CancerDrugs #OncologyBreakthrough #ChemoImmunotherapy #CancerR&D #HealthcareAdvances #PharmaceuticalTrends

[larvolclinic9]

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving sorafenib together with fulvestrant may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving sorafenib together with fulvestrant works in treating patients with locally advanced or metastatic breast cancer that did not respond to aromatase inhibitor therapy.Condition or disease Intervention/treatment Phase Breast CancerDrug: fulvestrantDrug: sorafenib tosylatePhase 2

Detailed Description:

OBJECTIVES:

Primary

To investigate the clinical activity of sorafenib tosylate and fulvestrant, as determined by a 4-month progression-free survival rate, in patients with hormone receptor-positive locally advanced or metastatic breast cancer that progressed after prior treatment with an aromatase inhibitor.

Secondary

To determine the objective response rate in patients treated with this regimen.

To determine the median time to progression in patients treated with this regimen.

To determine the progression-free survival of patients treated with this regimen.

To determine the overall survival of patients treated with this regimen.

To establish the safety and tolerability profile of this regimen in these patients.

OUTLINE: Patients receive oral sorafenib tosylate twice daily on days 1-28. Patients also receive fulvestrant intramuscularly on days 1 and 15 of course 1 and on day 1 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 28-56 days.

Study Design

MedlinePlus Genetics related topics: Breast cancer

MedlinePlus related topics: Breast Cancer

Drug Information available for: Fulvestrant Sorafenib

Genetic and Rare Diseases Information Center resources: Breast Cancer, Male

U.S. FDA Resources

[everythingwaschocolateandsugar]

Cancer Drug Market: Latest Treatment Methodology and Research Report 2022-2030

The global Cancer Drug Market report provides information on the state of the world's economies, along with a breakdown of the macroeconomic environment and business perspectives. The study provides an overview of trends and challenges facing these businesses. The research includes historical data and projections for the future, providing opportunities for these organizations.

The purpose of this study is to report on and effectively forecast the global Cancer Drug industry, which includes considerations for business cycles, demographics, and microeconomic factors. The global Cancer Drug market research project will also provide a number of opportunities to promote growth in income. As part of that work, this study evaluates the current business circumstances. This study also assesses a variety of financial factors, including production value and growth rate.

The competitive landscape of the Cancer Drug market includes key players such as -

Astellas Pharma Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, F. Hoffmann-La Roche ltd., Celgene Corporation, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC,), Pfizer Inc., Novartis AG.

This report offers a rundown of the biggest players in the Cancer Drug industry. This data will be useful for both established and emerging companies as it gives them a better understanding of how to plan their marketing strategies.

COVID-19 has changed the dynamics of global business by causing production facilities to struggle. The lockdowns have resulted in everything from small businesses to international corporations having trouble meeting demand.

Furthermore, there have been changes in consumer behavior toward spending patterns. These changes are influencing the types of products that are popular. For example, customers may purchase one product rather than a more expensive luxury item. However, as the industry is moving towards recovery from the pandemic, the global Cancer Drug market is projected to grow significantly in terms of revenue in the near future.

For the global study of the Cancer Drug market, different research methodologies were used, including primary and secondary research, a PESTEL and SWOT analysis, and Porter's Five Forces Model. This study was carried out with statistics and figures in order to provide a better understanding of prices, costs, revenues, and numbers.

The report offers a general overview of the Cancer Drug market, everything from sales to substance. It even covers a thorough analysis of supplier chains, retailers, and company execution across regional markets. Additionally, this research analyzes various segments of the global Cancer Drug market. This study will assist prominent players and other emerging players in the industry to evaluate production, marketing, and sales strategies with this data.

The Cancer Drug market is divided into the following categories based on Drug Class:

Chemotherapy

Targeted Therapy

Immunotherapy (Biologic Therapy)

Hormonal Therapy

The Cancer Drug market is divided into the following categories based on Indication:

Lung Cancer

Stomach Cancer

Colorectal Cancer

Breast Cancer

Prostate Cancer

Liver Cancer

Esophagus Cancer

Cervical Cancer

Kidney Cancer

Bladder Cancer

Other

Request For Free Samples: https://www.nextmsc.com/cancer-drug-market/request-sample

This global Cancer Drug market research report contains a number of different aspects of this industry. It talks about future growth opportunities, business plans, and sales. The report focuses on the forecasted market size along with market shares from companies in this field. Furthermore, the report accounts for economic and social factors that may impact the business to a higher degree than others. Some crucial data mentioned in this research report aims to help businesses develop appropriate strategies that can help them grow their business.

This report provides a deep and broad study of market dynamics and its various viewpoints in order to help companies fully execute their business plans and strategies against the ever-changing trends. Understanding the markets is essential for any company seeking to grow, lead and be competitive. The data quoted in this report has been collected through comprehensive and credible means to ensure accuracy.

The study includes forecasts for growing companies in the industry and the global market. The report pays close attention to the following regions: North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East. It focuses on future revenue prospects and the latest business trends. In other words, it helps businesses understand how they can grow their business through recent technological advancements.

About Us

Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For More Insights, Please Visit: https://www.nextmsc.com/

[seekmedindia]

The medical world recently witnessed a miracle during a cancer drug trial. A small group of patients with rectal cancer received a drug called Dostarlimab for six months and saw cancer vanish by the end of the trial. Nisha Varughese, a woman of Indian origin had also participated in the experimental treatment trial and has been cured of the tumour. Even though the treatment seems promising, the trial is yet to be conducted on a larger scale.

[mariebenz]

WHO: Profits Outweigh R&D Costs of New Cancer Drugs

MedicalResearch.com Interview with:

Dr. Kiu Tay-Teo Kiu Tay-Teo, PhD World Health Organization Geneva, Switzerland MedicalResearch.com: What are the main findings? Response: High costs and high risks of R&D for drugs have been presented to justify high drug prices, especially for cancer drugs. However, it is unclear whether prices are in fact justifiable compared to the overall return on R&D investment. In this paper, we systematically compared incomes from the sales of cancer drugs with the R&D costs. We quantified the incomes generated from the sales of 99 cancer drugs approved by FDA from 1989–2017. This was based on sales figures reported in the originator companies’ annual financial reports, and where necessary, estimates deduced from the reported figures. The sales incomes were net of rebates and discounts, but without accounting for expenses and taxes. For the R&D costs of bringing one new cancer drug to the market, the literature reported a typical costs of between $219 million and $2.9 billion, after accounting for the costs of failed products that were investigated but not marketed and the opportunity costs. For the main analysis, we used a median cost of $794 million, as reported in the literature. To be clear, this analysis did not estimate profit return because we do not have information about the costs and year-to-year variations in costs (i.e. expenses and taxes) specific to cancer drugs. MedicalResearch.com: What is the background for this study? Response: We found that by the end of 2017, originator companies have received, on average, $14.50 of sales income for every ‘risk-adjusted’ R&D dollar. About a third of the drugs studied had already qualified as “blockbuster drugs” because the average annual sales income exceeded $1 billion. We also found that many drugs, particularly biological products, continued to generate high sales incomes in the hundreds of millions for the originator companies after they are “off patents”. Our main analysis excluded 57 FDA-approved cancer drugs because data was insufficient. When we included the R&D costs for these excluded drugs but assumed an unrealistic zero income from them, the median return across all 156 medicines remained high at $8.80 for every dollar of R&D cost. When we doubled the estimated median R&D costs to $1588 million for all 99 included drugs, the median income return was $6.70, and the range of estimates was greater than $1 (i.e. more than enough to recover the R&D costs). MedicalResearch.com: What should readers take away from your report? Response: Cancer drugs, through high prices, have generated incomes for the companies far higher than their R&D costs. Despite the high returns for the companies, it is known that many healthcare systems and patients around the world cannot afford many cancer medicines because of their high price tags. Our results and observations from other published studies also suggest that the excessive returns might have contributed to inefficiencies in R&D of cancer drugs and stifled clinically meaningful innovation. For instance, cancer experts have pointed out the significant duplication of research efforts for drug candidates of the same or similar mechanisms of action/health conditions. They have also showed that many newer cancer drugs have not shown clinically meaningful benefits, and some may even cause more harms. Lowering prices of cancer drugs and facilitating greater competition are essential for improving patient access, health system’s financial sustainability, and future innovation. All stakeholders must come together to find a way to correct the unsustainable prices of cancer medicines.  MedicalResearch.com: What recommendations do you have for future research as a result of this work? Response: It would be informative to examine the returns in other therapeutic areas and the whole sector because there are notable examples of drugs with prices possibly disproportional to their benefits and innovativeness.  Disclosures We are WHO employees but the conclusions in the papers are ours as individuals and do not represent WHO policy.  Citation: Tay-Teo K, Ilbawi A, Hill SR. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies. JAMA Netw Open. 2019;2(1):e186875. doi:10.1001/jamanetworkopen.2018.6875  The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.   Read the full article

[technology-advisor]

6Technological Advancements in Medical fields that will Revolutionize the Future

Our modern life is more comfortable because of technology. f we want our daily life to be more comfortable, then technological advancements are most important. In recent years, technological advancements in the medical field give us hope to live without anxiety. Today we will discuss five technological advancements in medical fields that will revolutionize the future.

GENETIC EDITING

Treatments for genetically based diseases

When Chinese scientist He Jianku announced in November that he had manipulated twins’ DNA to not develop AIDS, all alarms went off. The situation imagined by many science fiction authors had materialized. Technology always advances at more speed than social debate and legislation. The use in human embryos of the genetic editing technique used by He, known as CRISPR/Cas9 or simply CRISPR, is heavily regulated. It allows DNA fragments to be cut and pasted at will and has been available since 2012. Besides, as it is cheap and straightforward, it is used in any laboratory that needs it, representing a breakthrough.

CRISPR technology’s main limitation is the lack of control over process errors, leading to unwanted genetic variations. According to Lluís Montoliu, a researcher at the CSIC’s National Centre for Biotechnology, “cutting can be controlled very well in the DNA sequence, but the same cannot yet be done with the repair.”

Drug development

Despite these limitations, this technique has already revolutionized biomedical research. It will continue to do so in the future, particularly in drug development and the treatment of diseases caused by genetic alterations. It is estimated that a single mutation causes about 10,000 diseases, so the technique’s potential is enormous. “All genetically based diseases are likely to be treated with CRISPR -says Montoliu-, although there are cases in which it can be easier or more difficult.”

Genetic editing allows, for example, to enhance a research technique known as knockout screening. By altering a gene, you can check what effects it causes, which can be used to identify targets for new drugs. Another thing that can be done is to solve resistance problems with certain medications. Gene silence allows us to see what genetic conditions cells are most sensitive to treatment so that compounds can be designed that act on the proteins produced thanks to the genes involved in resistance. This could improve, for example, chemotherapy in cases of pancreatic cancer. Another application of genetic editing is the possibility of introducing in mice the mutations that cause disease in a specific patient. Thus, treatments and ways to relieve symptoms can be tested accurately and personally.

But perhaps the area in which CRISPR technology is most promising is gene therapy. One way to implement this therapy is to extract the patient’s cells, edit them, select those that have not suffered any unwanted alteration, and re-inject them to the patient with the security that will not cause any unforeseen effect. This is already being used to treat blood diseases such as sickle cell anaemia and beta-thalassemia and boost immunotherapy in cancer cases. And it is expected that in the future this range of conditions will be expanded.

Clinical trials are also being carried out today to treat genetic diseases that affect sight. In this case, genetic editing tools are introduced directly into the eye. In this sense, explains Montoliu, “the eye is an accessible organ, which is isolated from the rest of the body and in which these therapies have already been tested, so doing so is relatively safe.”

ASSISTED REPRODUCTION

Three-person DNA embryos to treat infertility

Some arising from delayed maternity problems are forcing innovation in assisted reproduction treatments, increasing the effectiveness of treatments, and reducing their side effects. One of the main lines of research involves optimizing results. The success rate of embryo implantation is 30%, which can grow to 60% with a genetic diagnosis. “The personalization of reproductive medicine – with genetic diagnosis to determine which are the best embryos or with a genetic profile of the uterus to know what is the best time to transfer them – allows to increase the implantation rates,” explains Xavier Santamaria, Igenomix researcher and deputy scientific director of IVI, who augurs that in ten years it will be possible to reach “implementation rates of 90%”.

Other research lines have to do with tissue regeneration, big data, or ovarian rejuvenation. The most revolutionary is the nuclear transfer technique or maternal spindle transfer, which is popularly referred to as the embryo of three genetic parents. It uses the DNA of three people. It is about extracting the nucleus from the mother’s egg and introducing it into the donor’s egg, from which the original nucleus has previously been extracted. The result is an egg with the cytoplasm free of defective mitochondria and a nucleus with the mother’s inheritance. It is then fertilized in vitro with the father’s sperm and implanted in the mother’s uterus. This technique, however, has only been used within the framework of clinical trials. The United Kingdom was the first country to give the green light to prevent the transmission of mitochondrial diseases. The world’s first baby conceived like this was born in 2016 in Mexico. The novelty is that it has now been used not to prevent disease but to solve infertility problems: on April 9, the first child was born in Athens thanks to the collaboration of the Institute of Life assisted reproduction centre in Athens and Embryotools, the company based at the Barcelona Science Park that has developed the technique. “It has an important application because many couples with fertility problems now have no solution unless it is with conventional oocyte donation. It works very well, but genetically these babies are not related to the mother, which causes couples difficulty accepting it,” says Nuno Costa-Borges, scientific director of Embryotools. The child resulting from this assisted reproduction technique is related to the biological father and mother by more than 99% since the donor only provides mitochondrial DNA, which accounts for less than 1% of the cell. That is why Costa-Borges refuses to talk about “children of three parents” because it “leads to confusion.”

Ethical debate

However, the technique is still in the experimental period – the pilot trial is being conducted in Greece – and it would take the endorsement of the National Commission for Assisted Human Reproduction to apply it in Spain. It is a technique not without controversy since many of these fertility problems could be solved with donated eggs without the need to modify them to introduce the mother’s nuclear DNA. Besides, some voices warn that the baby’s consequences are unknown, although Costa-Borges assures that the former has been born healthy. “Science is advancing faster than laws, and it is important that Spain, a leading country in egg donation, can allow it in a regulated area,” he says. In any case, it cannot be incorporated into clinical practice overnight, as special technology and training are needed.

TISSUE BIOPRINTING

Custom fabrics thanks to bioprinting

At present, the only known cases of organs printed in the laboratory and successfully implanted in people are those of five Chinese children affected by microtia, a deformation of the ear of genetic origin. A team of Chinese scientists explained a year ago that they had managed to combine 3D printing with cultivation techniques to generate ears that they successfully implanted in five cases.

Although we are still far from creating organs such as kidneys in the laboratory and transplanting them into a person, current tissue printing technology opens up a set of new applications. First, it is now possible to recreate patients’ laboratory tissues from images of the real tissue. This allows complicated testing surgeries in the laboratory so that when the patient intervenes, the procedure is safer. It is being done thanks to the new bioengineering departments in hospitals such as Sant Joan de Déu or Clínic de Barcelona and is expected to increase.

This technology also creates low-vascularized body parts, such as heart valves, skin, tendons, and cartilage. These objects are printed with an ink that mimics the protein structure of real tissue. In the case of heart valves and tendons, they are already being tested in mice. “We can do it thanks to all the basic research on these tissues that have been developed over the last few years,” explains Núria Montserrat, a researcher at the Institute for Bioengineering of Catalonia (IBEC).

Thanks to this knowledge, in the future personalized tissues, can be printed from real images of the tissue to be regenerated so that the fit between the implant and the receiving organism improves considerably. In this sense, Montserrat and her team also work to obtain materials with which fabrics that do not generate rejection can be printed when they are implanted.

Bioprinting also opens a new pathway in drug testing. There are already companies that print tissues such as the liver, in which the toxicity of certain drugs can be studied so that, in the future, the process of creation and pharmacological trial can be shortened.

MICROBIOTA AND IMMUNE SYSTEM

Modulation of the body’s defence system

In recent years, the set of microorganisms that live in the guts, especially bacteria, has a significant impact on health. Known as microbiota, they help develop the guts’ anatomy, stimulate the immune system of babies, participate in food digestion and vitamin production, and play an essential role in assimilating drugs. The study of the relationship between the microbiota and the immune system is an incipient field of research that can improve vaccine efficiency, cancer treatments, allergies, and autoimmune diseases.

“We are starting to see a relationship between the immune system response and the nature of the microbiota,” explains Roger Paredes, a researcher at the IrsiCaixa AIDS Research Institute. For example, in mice, it has already been observed that there are eleven species of bacteria that stimulate an immune response capable of fighting HIV and some cancers. According to the researcher, “moving from mice to humans is complicated, but this knowledge is promising.”

Scientists’ idea is to modulate the immune system response depending on the disease by administrationing the good bacteria. In this way, this response could be intensified in cases of infections and cancer and attenuate it in allergies and autoimmune diseases. “We’re talking about bacteria that still can’t be bought in pharmacies,” Paredes clarifies. The research carried out so far in the laboratories opens up new and exciting perspectives.

CELL THERAPY LULAR FOR CANCER

CAR-T, a promising strategy to treat leukaemias

Car-T cell therapy (Chimeric Antigen Receptor T-Cells) has been a “step forward” in curing certain haematological cancers but has not yet developed its full potential. “We have not removed all the juice,” acknowledges Josep Maria Ribera, head of haematology at the Catalan Institute of Oncology (ICO) Badalona and expert in cell therapy. CAR-T cell therapy consists of genetically modifying the cells of the same patient’s immune system to make them recognize and attack tumour cells. A specific type of cells are selected, T lymphocytes – immune system cells extracted from the patient’s blood and treated to introduce genes made into the laboratory, which act as a kind of “weapon” to specifically identify tumour cells attack them more aggressively. “We modify them to destroy tumour cells,” explains Ribera. These modified cells are siphoned to the patient intravenously.

When all options failed

This therapeutic strategy brings together one of the three most cutting-edge lines in the approach to cancer: immunotherapy, targeted therapy, and genetic editing. And it has become one of the most promising therapeutic approaches for haematological cancers -basically lymphoma, acute lymphoblastic leukemia, and myeloma-. The challenge is that it can be transferred to solid tumours. CAR-T therapy is reserved for cases where the rest of the treatments have failed because, as Ribera acknowledges, it has “lights and shadows.” On the one hand, it has proven very useful in the short term, but it plays against its toxicity, and that there is still a lack of data to determine its long-term effectiveness. “We are seeing patients relapsing, and that makes us think it is not the ultimate weapon. It is effective and has a great future, it will be an advantage for many patients, but from here to cure cancer, there is still a long way”.

Ribera calls the advance “substantial” – especially since it is a hope for patients who could only be offered palliative care – but says it will have to be time to say if it is a revolution. “The possibility of development is immense, but I trust more in the CAR-T of the future than in those of the present. The story of the CAR-T is yet to be written; we have only begun it,” he concludes.

‘BIG DATA’ AND VIRTUAL REALITY

Artificial intelligence to help the doctor decide

“There is no other sector in which data generation is as high and goes at as much speed as medicine,” says Carolina García Vidal, a specialist in the infectious diseases service at Hospital Clínic. And now, this data can already be used for the benefit of the patient. “Artificial intelligence is present, and the creation of automated algorithms helps us to make clinical decisions,” explains García Vidal, who highlights that it is an “innovative” approach. “We are able to use large volumes of data from electronic clinical histories to create algorithms for predicting what will happen to our patients,” he adds. An example is the algorithm they have created to predict with a reliability of 98% which cancer patients will develop infections by multiresistant microorganisms and which will not, which allows to adjust the initial treatments to the real need and minimize side effects. It is estimated that one in four of these patients with multiresistant infection receives incorrect treatment. This figure is reduced to 2% with the algorithm, resulting in reduced antibiotic consumption, less toxicity, and lower economic costs.

Artificial intelligence also has applications in imaging techniques. There are experiences to diagnose skin, breast, and lung tumours and eye diseases or interpret scanners or resonances. For García Vidal, this is the beginning of a story that will “revolutionize medicine,” since now the prediction of the patient’s evolution is based on experience and what the medical literature says. At the same time, “in the future-present, we will have a lot of data processed by artificial intelligence that will make accurate predictions and personalized treatments.” They will not replace; however, the doctors: “They will complement the doctor’s mind; they will make our lives easier.”

Virtual reality to reduce pain Another example of technology applied to medicine is virtual reality to reduce patients’ pain and distress when faced with medical procedures such as surgical intervention. The Hospital Mútua de Terrassa has done a pilot test to reduce cancer patients’ pain when they leave the operating room, and the SJD Barcelona Children’s Hospital uses it for children who undergo magnetic resonances. Immersive technology has a promising potential as a painkiller effect and is also a useful tool for treating phobias, as they do at the Quirón Dexeus University 

[pvpharma]

Dacarbazine for Injection USP

Dacarbazine is a cancer medication that interferes with the growth and spread of cancer cells in the body. Dacarbazine is used to treat skin cancer (malignant melanoma) and Hodgkin’s disease. Dacarbazine may also be used for purposes not listed in this medication guide. 

[fromsciencetopharma]

FDA to scrutinize unproven cancer drugs after 10-year gap #FDA #cancerdrugs “Each year the U.S. approves dozens of new uses for cancer drugs based on early signs that they can shrink or slow the spread of tumors. But how often do those initial results translate into longer, healthier lives for patients? That seemingly simple question is one of the thorniest debates in medicine. It spills into public view Tuesday as the Food and Drug Administration convenes the first meeting in a decade to consider clawing back approvals from several cancer drugs that have failed to show they extend or improve life. The agency says it has used innovative research shortcuts to speed up the availability of medicines for desperately ill patients. But many researchers say it has failed to crack down on medications that don't deliver on their early promise, leaving a glut of expensive, unproven cancer drugs on the market. The U.S. spends more per person on prescription drugs than any other nation, and spending on cancer drugs has more than doubled since 2013 to over $60 billion annually, according to IQVIA. New medications typically cost $90k to $300k a year. “ Read more in comments... #medicalaffairs #MSLS https://www.instagram.com/p/COKcp06jBQ_/?igshid=1vw6vsi2vvyid

[simplicityrealestate]

University of Florida College of Pharmacy reveals breakthrough cancer drug

[farwiayas3-blog]

A Cancer-Drug Pricing Experiment Gets More Interesting:... - https://goo.gl/ARf7Lh - #Auto_Insurance, #CancerDrug, #Experiment, #Interesting, #Pricing

[mariebenz]

Only 1 in 5 Cancer Drugs Receiving FDA Accelerated Approval Have Proven Benefits in Confirmatory Trials

MedicalResearch.com Interview with:

Dr. Gyawali Bishal Gyawali  MD PhD Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts Department of Oncology, Department of Public Health Sciences, and Division of Cancer Care and Epidemiology, Queen’s University, Kingston, Ontario, Canada MedicalResearch.com: What is the background for this study? What are the main findings? Response: Accelerated approval pathway from the FDA allows cancer drugs to come to market sooner by showing improvement in surrogate measures such as change in tumor size. Surrogate measures do not reflect clinical benefit in terms of living longer or feeling better. So, when a drug receives accelerated approval, the drug is required to undergo a confirmatory trial to confirm that true clinical benefit from the drug actually exists. Last year, a paper from the FDA argued that accelerated approval pathway is working effectively because 55% of such drugs confirmed clinical benefit. However, we saw that most of those drugs were actually improving only a surrogate measure even in confirmatory trials. So the confirmatory trials were not confirming clinical benefit but actually confirming benefit in a surrogate endpoint. We investigate that issue in our study using updated results from the confirmatory trials that were ongoing at the time of FDA review. Our main finding is that only one-fifth of cancer drugs that received accelerated approval actually improved overall survival later in confirmatory trials. For, 20% of other drugs, the confirmatory trials tested the same surrogate endpoint as did the preapproval trial. For another 21%, the confirmatory trial showed benefit in a surrogate endpoint different from the one used in preapproval trial. Furthermore, when drugs fail to confirm clinical benefits in confirmatory trials, they still continue to remain on market.  MedicalResearch.com: What should readers take away from your report? Response: Only 20% of cancer drugs approved using accelerated approval pathway have proven benefits in overall survival in a confirmatory trial. Even when the trials are called confirmatory, usually they just confirm effect on surrogate measures and do not confirm actual clinical benefit. Sometimes, when the drug fails in confirmatory trial, appropriate actions to withdraw the drug from the market are rarely taken.  MedicalResearch.com: What recommendations do you have for future research as a result of this work? Response: We have policy recommendations rather than research recommendations from our study. We recommend that the success of accelerated approval pathway lies in the fact that confirmatory studies are duly conducted in time, and use clinical endpoints such as overall survival or quality of life to actually confirm benefit rather than test another surrogate measure. When drugs fail in confirmatory studies, quick and decisive steps must be taken to withdraw the drug from the market to prevent undue harm from unhelpful drugs. That is how accelerated approval pathway is supposed to function keeping patient benefits at the center of the agenda. MedicalResearch.com: Is there anything else you would like to add?  Response: In a different paper from last year, we provide 3 suggestions to reinforce the social compromise of AA: https://www.nature.com/articles/s41571-018-0066-3 We have no financial conflicts to disclose. Other disclosures are as mentioned in the paper.  Citation: Gyawali B, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Intern Med. Published online May 28, 2019. doi:10.1001/jamainternmed.2019.0462   The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.   Read the full article

[pvpharma]

Treating symptoms of certain types of cancer (multiple myeloma, ovarian cancer). It may also be used for other conditions as determined by your doctor. Melphalan tablets are an alkylating agent. It works by destroying resting and rapidly dividing tumor cells in certain types of cancer.